Biotech investors are having some not-so-happy holidays.
In the last few months, several major funds have reportedly seen double-digit drops in their biotech portfolios’ value — leading some to wonder if the sector’s remarkable run is really, finally over this time.
But at a recent STAT event in New York, Casdin Capital founder Eli Casdin seemed unconcerned about biotech’s long-term prospects.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.